Prato

• Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re … Recruiting
  2022-501308-90-00 4 2023-05-24 Molecularly selected and resectable primary colorectal cancer
• 68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket) Recruiting
  2024-511659-17-00 4 2023-05-01 Solid tumors
• Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minima … Recruiting
  2024-515681-14-00 4 2022-05-02 Stage II (pT4)/III colorectal cancer with positive circulating tumor D
• A Randomized & Observational phase II trial comparing the activity of TrabectedIn vs gemCitabine in patients with metastatic or locally adva … Recruiting
  2024-513820-40-00 4 2021-10-29 Metastatic or locally advanced leiomyosarcoma
• Phase II study on trabectedin in adults and young adults HEY1-NOCA2 positive skeletal and extra-skeletal mesenchymal chondrosarcoma (MCS) Recruiting
  2024-514319-85-00 4 2021-09-14 Advanced rearranged mesenchymal chondrosarcoma
• Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva … Recruiting
  2024-513372-18-00 4 2019-10-18 Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended recruitment
  2023-510341-19-00 5 2024-11-14 acne vulgaris
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil … Ended recruitment
  2023-510342-24-00 5 2024-11-11 Acne vulgaris
• A PHASE 1/2 STUDY EXPLORING THE SAFETY AND ACTIVITY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH CAPECITABINE AND BEVACIZUMAB IN METASTATIC … Ended recruitment
  2024-513271-41-00 4 2024-09-16 colorectal metastatic cancer
• Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study Ended recruitment
  2023-509088-26-00 4 2024-07-22 Metastatic colorectal cancer
• Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended recruitment
  2022-502145-10-00 5 2023-06-06 Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U … Ended recruitment
  2023-504194-21-00 5 2022-09-13 PD-L1 Positive Metastatic Triple-Negative Breast Cancer
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca … Ended recruitment
  2023-509631-37-00 5 2022-01-18 "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
• ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoa … Ended recruitment
  2024-513297-21-00 4 2022-01-14 Locally advanced rectal cancer
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph … Ended recruitment
  2024-511636-27-00 5 2021-12-01 Follicular Lymphoma
• RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB … Ended recruitment
  2024-518847-40-00 4 2021-07-16 recurrent ovarian cancer
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello- … Ended recruitment
  2023-504997-39-00 5 2021-06-14 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can … Ended recruitment
  2024-513296-41-00 4 2020-12-03 Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended recruitment
  2024-510776-20-00 5 2019-10-25 Female or male patients with histologically confirmed HR-positive, HER
• IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended recruitment
  2024-517489-41-00 5 2017-03-27 High-risk stage III colon cancer

Showing 25–48 of 56 trials